Ð’Ð¸Ð·Ð½Ð°Ñ‡ÐµÐ½Ð½Ñ Ñтану Т-клітинної ланки імунітету Ñ– вміÑту Ñтовбурових ракових клітин Ñк критерій оцінки ефективноÑті превентивної терапії раку молочної залози кріоконÑервованими клітинами фетальної печінки
The expediency to use cryopreserved fetal liver cells (cFLCs) for preventive treatment of breast cancer (BC) is proved by a wide range of produced by them biologically active substances with immunomodulatory and antineoplastic activity. Revealing cancer stem cells (CSCs) in the mammary gland (MG) an...
Збережено в:
Дата: | 2014 |
---|---|
Автори: | , , , , , |
Формат: | Стаття |
Мова: | English |
Опубліковано: |
Publishing House ‘Akademperiodyka’ of the National Academy of Sciences of Ukraine; Institute for Problems of Cryobiology and Cryomedicine
2014
|
Теми: | |
Онлайн доступ: | https://cryo.org.ua/journal/index.php/probl-cryobiol-cryomed/article/view/717 |
Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Назва журналу: | Problems of Cryobiology and Cryomedicine |
Репозитарії
Problems of Cryobiology and CryomedicineРезюме: | The expediency to use cryopreserved fetal liver cells (cFLCs) for preventive treatment of breast cancer (BC) is proved by a wide range of produced by them biologically active substances with immunomodulatory and antineoplastic activity. Revealing cancer stem cells (CSCs) in the mammary gland (MG) and determination of the immune system (IS) status are the methods of early diagnosis and evaluation of preventive treatment efficiency of breast cancer. The experiments were performed in 16-month-old C3H/He mice which in 6 months were injected by cryopreserved or native FLCs of 14 gestation days at a dose of 1×106 or 5×106 cells. Probl Cryobiol Cryomed 2014; 24(3):238-248. |
---|